Safusidenib
From Wikipedia, the free encyclopedia
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | AB-218; DS-1001; DS-1001b |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H18Cl3FN2O4 |
| Molar mass | 535.78g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Safusidenib is an investigational new drug that is being evaluated by AnHeart Therapeutics and the Daiichi Sankyo Company for the treatment of IDH1-mutant glioma. It is a isocitrate dehydrogenase 1 inhibitor.[1] [2]
Clinical trials
[edit ]Safusidenib is in phase 3 clinical trials for IDH1-mutant glioma.[3]
References
[edit ]- ↑ "Safusidenib - Daiichi Sankyo Company; National Cancer Center (Tokyo)". AdisInsight. Springer Nature Switzerland AG.
- ↑ Lanman TA, Gonzalez Castro LN (August 2025). "Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review". Cancers. 17 (16). Basel: 2630. doi:10.3390/cancers17162630 . PMC 12384762 . PMID 40867259.
- ↑ Clinical trial number NCT05303519 for "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)" at ClinicalTrials.gov
Stub icon
This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.